권호기사보기
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
대표형(전거형, Authority) | 생물정보 | 이형(異形, Variant) | 소속 | 직위 | 직업 | 활동분야 | 주기 | 서지 | |
---|---|---|---|---|---|---|---|---|---|
연구/단체명을 입력해주세요. |
|
|
|
|
|
* 주제를 선택하시면 검색 상세로 이동합니다.
Purpose The role of allogeneic stem cell transplantation (alloSCT) in multiple myeloma (MM) treatment remains controversial. We conducted a retrospective, multicenter, nationwide study in Korea to evaluate the outcomes of alloSCT in Asian patients with MM.
Materials and Methods Overall, 109 patients with MM who underwent alloSCT between 2003 and 2020 were included in this study. Data were collected from the Korean Multiple Myeloma Working Party Registry.
Results The overall response rate and stringent complete response plus complete response (CR) rates were 67.0 and 46.8%, respectively, after alloSCT. At a median follow-up of 32.5 months, the 3-year probability of progression-free survival (PFS) and overall survival (OS) rates were 69.3% and 71.8%, respectively. The 3-year probabilities of OS rates in the upfront alloSCT, tandem auto-alloSCT, and later alloSCT groups were 75.0%, 88.9%, and 61.1%, respectively. Patients who achieved CR before or after alloSCT had significantly longer OS (89.8 vs. 18 months and 89.8 vs. 15.2 months, respectively). Even though patients who did not achieve CR prior to alloSCT, those who achieve CR after alloSCT had improved PFS and OS compared to those who had no achievement of CR both prior and after alloSCT. Patients who underwent alloSCT with 1-2 prior treatment lines had improved PFS (22.4 vs. 4.5 months) and OS (45.6 vs. 15.3 months) compared to those with three or more prior treatment lines.
Conclusion AlloSCT may be a promising therapeutic option especially for younger, chemosensitive patients with earlier implementation from relapse.번호 | 참고문헌 | 국회도서관 소장유무 |
---|---|---|
1 | J Korean Med Sci. 2007 Apr;22(2):227-34 | 미소장 |
2 | Biol Blood Marrow Transplant. 2016 Oct;22(10):1893-1899 | 미소장 |
3 | Bone Marrow Transplant. 2015 Apr;50(4):505-10 | 미소장 |
4 | Bone Marrow Transplant. 2014 Mar;49(3):416-21 | 미소장 |
5 | J Clin Oncol. 2010 Oct 10;28(29):4521-30 | 미소장 |
6 | Biol Blood Marrow Transplant. 2013 Jun;19(6):860-6 | 미소장 |
7 | Bone Marrow Transplant. 2017 Dec;52(12):1602-1608 | 미소장 |
8 | Cancer. 2006 Mar 1;106(5):1084-9 | 미소장 |
9 | Blood. 2005 Nov 1;106(9):2969-76 | 미소장 |
10 | Bone Marrow Transplant. 2008 Jun;41(11):953-60 | 미소장 |
11 | Blood. 2008 Nov 1;112(9):3591-3 | 미소장 |
12 | Leukemia. 2006 Sep;20(9):1467-73 | 미소장 |
13 | Transplantation. 1974 Oct;18(4):295-304 | 미소장 |
14 | Haematologica. 2007 Nov;92(11):1513-8 | 미소장 |
15 | Blood. 2009 Apr 2;113(14):3383-91 | 미소장 |
16 | Transfus Apher Sci. 2016 Feb;54(1):63-70 | 미소장 |
17 | Bone Marrow Transplant. 2009 Sep;44(5):325-6 | 미소장 |
18 | Biol Blood Marrow Transplant. 2018 Jul;24(7):1392-1398 | 미소장 |
19 | Blood. 2008 Mar 1;111(5):2516-20 | 미소장 |
20 | Br J Haematol. 2001 Apr;113(1):209-16 | 미소장 |
21 | N Engl J Med. 2011 Mar 17;364(11):1046-60 | 미소장 |
22 | Bone Marrow Transplant. 2013 Nov;48(11):1395-400 | 미소장 |
23 | Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051 | 미소장 |
24 | Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31 | 미소장 |
25 | Biol Blood Marrow Transplant. 2013 Oct;19(10):1453-8 | 미소장 |
26 | Blood. 2004 Jan 1;103(1):20-32 | 미소장 |
27 | Biol Blood Marrow Transplant. 2012 Apr;18(4):617-26 | 미소장 |
28 | Leukemia. 2014 Mar;28(3):525-42 | 미소장 |
*표시는 필수 입력사항입니다.
*전화번호 | ※ '-' 없이 휴대폰번호를 입력하세요 |
---|
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
번호 | 발행일자 | 권호명 | 제본정보 | 자료실 | 원문 | 신청 페이지 |
---|
도서위치안내: 정기간행물실(524호) / 서가번호: 국내16
2021년 이전 정기간행물은 온라인 신청(원문 구축 자료는 원문 이용)
우편복사 목록담기를 완료하였습니다.
*표시는 필수 입력사항입니다.
저장 되었습니다.